![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sanofi’s Sarclisa Nabs FDA Approval for Previously-Treated Multiple Myeloma
Sanofi’s Sarclisa Nabs FDA Approval for Previously-Treated Multiple Myeloma
The FDA approved Sanofi’s Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
The approval was based on the results of a clinical trial in which patients who received Sarclisa in combination with pom-dex demonstrated a statistically significant improvement in progression free survival.
Sarclisa received an orphan drug designation from the FDA and European Medicines Agency.
Upcoming Events
-
21Oct